Addressing Treatment Resistance & Improving Outcomes in Retinal Vein Occlusion with a Novel Multimodal Eye Drop Therapy
Time: 11:00 am
day: Day One
Details:
- Overview of the E147 eye drop, a second-generation product targeting retinal vein occlusions with a unique mechanism of action
- Highlight the positive results from the pilot study and plans for upcoming US trials in retinal vein occlusion and diabetic retinopathy
- Discuss how the E147 eye drop’s ability to target multiple growth factors involved in vascular and fibrotic processes could help address the issue of treatment resistance and fibrosis associated with current anti-VEGF therapies
